The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis
Abstract
OBJECTIVES: To update the evidence for associations between antibiotic classes and hospital-acquired Clostridium difficile infection (HA-CDI). METHODS: Electronic databases of journal articles, scholarly theses and conference proceedings using subject headings and keywords related to CDI and antibiotic exposure were searched. Observational epidemiological studies measuring associations between antibiotic classes and HA-CDI were eligible for inclusion. Pooled ORs and 95% CIs were calculated using a random effects model. Study factors identified a priori were examined as sources of heterogeneity. The quality of the studies was assessed using the Newcastle-Ottawa Scale. RESULTS: Of 569 citations identified, 13 case-control and 1 cohort study (15,938 patients) were included. The strongest associations were found for third-generation cephalosporins (OR = 3.20, 95% CI = 1.80-5.71; n = 6 studies; I(2) = 79.2%), clindamycin (2.86, 2.04-4.02; n = 6; I(2) = 28.5%), second-generation cephalosporins (2.23, 1.47-3.37; n = 6; I(2) = 48.4%), fourth-generation cephalosporins (2.14, 1.30-3.52; n = 2; I(2) = 0.0%), carbapenems (1.84, 1.26-2.68; n = 6; I(2) = 0.0%), trimethoprim/sulphonamides (1.78, 1.04-3.05; n = 5; I(2) = 70%), fluoroquinolones (1.66, 1.17-2.35; n = 10; I(2) = 64%) and penicillin combinations (1.45, 1.05-2.02; n = 6; I(2) = 54%). The study population and the timing of measurement of antibiotic exposure were the most common sources of heterogeneity. Study quality scored high for seven studies, moderate for six studies and low for one study. CONCLUSIONS: The risk of HA-CDI remains greatest for cephalosporins and clindamycin, and their importance as inciting agents should not be minimized. The importance of fluoroquinolones should not be overemphasized, particularly if fluoroquinolone-resistant epidemic strains of C. difficile are absent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
(2014) · Medical Entomology and Zoology · Cited by 17,633
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010) · International Journal of Surgery · doi:10.1016/j.ijsu.2010.02.007 · Cited by 12,156
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Muto, C. A., Pokrywka, M., Shutt, K., Mendelsohn, A. B., Nouri, K., Posey, K., Roberts, T., Croyle, K., Krystoflak, S., Patel-Brown, S., et al. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502539 · Cited by 619
Antimicrobial‐Associated Risk Factors for Clostridium difficile Infection
Owens, Jr., Donskey, C. J., Gaynes, R. P., Loo, V. G., & Muto, C. A. (2008) · Clinical Infectious Diseases · doi:10.1086/521859 · Cited by 603
Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection
Brown, K. A., Khanafer, N., Daneman, N., & Fisman, D. N. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02176-12 · Cited by 587
Recommendations for Surveillance of Clostridium difficile–Associated Disease
McDonald, L. C., Coignard, B., Dubberke, E., Song, X., Horan, T., Kutty, P. K., & the Ad Hoc Clostridium difficile Surveillance Working Group (2007) · Infection Control & Hospital Epidemiology · doi:10.1086/511798 · Cited by 558
Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics
Hensgens, M. P. M., Goorhuis, A., Dekkers, O. M., & Kuijper, E. J. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr508 · Cited by 399
Meta-analysis in Stata : an updated collection from the Stata journal
Palmer, T., & Sterne, J. A. C. (2015) · Medical Entomology and Zoology · Cited by 388
Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review
Thomas, C. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg254 · Cited by 305
The economic burden of Clostridium difficile
McGlone, S. M., Bailey, R. R., Zimmer, S. M., Popovich, M. J., Tian, Y., Ufberg, P., Muder, R. R., & Lee, B. Y. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03571.x · Cited by 206
Fluoroquinolone Use and Clostridium difficile–associated Diarrhea
McCusker, M. E., Harris, A. D., Perencevich, E., & Roghmann, M.-C. (2003) · Emerging Infectious Diseases · doi:10.3201/eid0906.020385 · Cited by 200
Asha, N. J., Tompkins, D., & Wilcox, M. H. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00165-06 · Cited by 194
Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection
Dial, S., Kezouh, A., Dascal, A., Barkun, A., & Suissa, S. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071812 · Cited by 166
Baxter, R. P., Ray, G. T., & Fireman, B. H. (2007) · Infection Control and Hospital Epidemiology · doi:10.1086/524320 · Cited by 151
Clostridium difficileRibotype 027, Toxinotype III, the Netherlands
Kuijper, E. J., van den Berg, R. J., Debast, S. B., Visser, C. E., Veenendaal, D., Troelstra, A., van der Kooi, T. I. I., van den Hof, S., & Notermans, D. W. (2006) · Emerging infectious diseases · doi:10.3201/eid1205.051350 · Cited by 140
Kallen, A. J., Thompson, A. D., Ristaino, P., Chapman, L., Nicholson, A. C., Sim, B.-T. T., Lessa, F. C., Sharapov, U. M., Fadden, E., Boehler, R., et al. (2009) · Infection Control and Hospital Epidemiology · doi:10.1086/595694 · Cited by 87
Vardakas, K. Z., Konstantelias, A. A., Loizidis, G., Rafailidis, P. I., & Falagas, M. E. (2012) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2012.07.010 · Cited by 76
Polgreen, P. M., Chen, Y., Cavanaugh, J. E., Ward, M., Coffman, S. L., Hornick, D. B., Diekema, D. J., & Herwaldt, L. A. (2007) · Infection Control and Hospital Epidemiology · doi:10.1086/512174 · Cited by 71
Lambert, P. J., Dyck, M., Thompson, L. H., & Hammond, G. W. (2009) · Infection Control and Hospital Epidemiology · doi:10.1086/605719 · Cited by 71
Clostridium difficile Among Hospitalized Patients Receiving Antibiotics A Case-Control Study
Modena, S., Bearelly, D., Swartz, K., & Friedenberg, F. K. (2005) · Infection Control and Hospital Epidemiology · doi:10.1086/502603 · Cited by 67
Vesta, K. S., Wells, P. G., Gentry, C. A., & Stipek, W. J. (2005) · American Journal of Infection Control · doi:10.1016/j.ajic.2005.06.004 · Cited by 41
The Incidence and Clinical Features ofClostridium difficileInfection; Single Center Study
Lee, J. H., Lee, S.-Y., Kim, Y. S., Park, S.-W., Park, S. W., Jo, S. Y., Ryu, S. H., Lee, J. H., Moon, J. S., Whang, D. H., et al. (2010) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2010.55.3.175 · Cited by 24
Brote nosocomial de diarrea por Clostridium difficile en un servicio de cirugía vascular
Pazosa, R., Isusia, A., Fernándeza, R., Barbeitob, L., Bravoa, A., Cantóna, I., Gayosoc, P., & Lebratod, R. (2003) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(03)72929-2 · Cited by 7
Relationship between Antibiotic Exposure and Subsequent Clostridium Difficile-Associated Diarrhea
Minson, Q., & Mok, S. (2007) · Hospital Pharmacy · doi:10.1310/hpj4205-430 · Cited by 5
Cited by
Clostridium difficile infection
Smits, W. K., Lyras, D., Lacy, D. B., Wilcox, M. H., & Kuijper, E. J. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.20 · Cited by 853
Antibiotics as deep modulators of gut microbiota: between good and evil
Ianiro, G., Tilg, H., & Gasbarrini, A. (2016) · Gut · doi:10.1136/gutjnl-2016-312297 · Cited by 625
Diagnosis and Treatment of Clostridium difficile in Adults: A Systematic Review
Bagdasarian, N., Rao, K., & Malani, P. N. (2015) · JAMA · doi:10.1001/jama.2014.17103 · Cited by 451
Unravelling the collateral damage of antibiotics on gut bacteria
Maier, L., Goemans, C. V., Wirbel, J., Kuhn, M., Eberl, C., Pruteanu, M., Müller, P., Garcia-Santamarina, S., Cacace, E., Zhang, B., et al. (2021) · Nature · doi:10.1038/s41586-021-03986-2 · Cited by 391
The gut microbiome’s role in the development, maintenance, and outcomes of sepsis
Adelman, M. W., Woodworth, M. H., Langelier, C., Busch, L. M., Kempker, J. A., Kraft, C. S., & Martin, G. S. (2020) · Critical Care · doi:10.1186/s13054-020-02989-1 · Cited by 342
Metadata
- Authors
- Slimings, C., & Riley, T. V.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-12-08
- Volume
- 69
- Issue
- 4
- Pages
- 881-891
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2100217657
- Cited by
- 581
- References
- 31
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.